Uncategorized

Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan

Nicox SA announced the signature of an agreement granting Kowa Company, Ltd., a Japanese company with a global pharmaceutical business engaged in ground-breaking research, development and marketing, exclusive Japanese rights to develop and commercialize NCX 470, Nicox’s nitric oxide (NO)-donating bimatoprost eye drop, for the lowering of intraocular pressure (IOP) in patients with glaucoma or

Nicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in Japan Read More »

Scroll to Top